Korean Practice Patterns for Screening PCA(Prostate Cancer) (RESPECT)

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01371513
First received: May 12, 2011
Last updated: November 3, 2011
Last verified: October 2011
  Purpose

This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.


Condition Intervention
Neoplasms, Prostate
Prostate Cancer
Benign Prostatic Hyperplasia
Other: continuous screening

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of subjects with prostate biopsy [ Time Frame: 1year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of subjects with prostate cancer [ Time Frame: 1year ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: May 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
PSA level
more than 2.5ng/ml
Other: continuous screening
practice patterns for screening prostate cancer

Detailed Description:

This is to investigate Korean urologist's practice patterns for screening prostate cancer according to PSA level.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Subjects with PSA more than 2.5ng/ml in 2008 from urology department of clinic and general hospital

Criteria

Inclusion Criteria:

  • Male with PSA more than 2.5ng/ml from 1 Jan 2008 to 31 Dec 2008

Exclusion Criteria:

  • Age less than 40 at PSA screening
  • History of drug use which can affect level of PSA within 6months before PSA screening
  • Subject who participate any other clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01371513

Locations
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 135-720
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01371513     History of Changes
Other Study ID Numbers: 113951
Study First Received: May 12, 2011
Last Updated: November 3, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by GlaxoSmithKline:
Serum prostate specific antigen

Additional relevant MeSH terms:
Hyperplasia
Prostatic Hyperplasia
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014